The pharmaceutical industry continues to face a multitude of changes that have the potential to directly impact launch strategy. From more recent tangible trends like a rise in cost-containment policies, to ongoing net price transparency forces and a focus on health equity, the potential to make mistakes during launch is growing. Reasons for traditional launch […]
Noticeable improvements in several relationship competencies separate the top companies from the rest of the industry. Post-pandemic industry dynamics have forced a shift in the way pharmaceutical companies call on their managed care customers. This past month, NAVLIN Insights concluded our annual research with payer pharmacy directors assessing their relationships and interactions with the pharmaceutical […]
Assessment of Strategic Priorities, Competitive Dynamics, and Innovations Impacting Biopharma Access Seven leading payers represent nearly half of all US medical lives and 54% of pharmacy lives: UnitedHealth Group CVS Health, Cigna Elevance Health Kaiser Permanente Humana Centene As these organizations evolve their business models and ultimately their approaches to care and drug management, biopharma […]
The pharmacy benefit biologic market is primed for disruption, with Specialty Pharmacies (SPs) eagerly awaiting the pending market shift. While biosimilars have been available for nearly a decade in the United States, this year will be the first time many SPs begin dispensing these brands. Currently, 22 biosimilars are available in the U.S. and, up […]
The pharmaceutical industry faces a host of increasingly complex challenges and critical decisions when attempting to manage and predict their products’ plausible revenue patterns. The mishandling of revenue forecasting and evaluation can result in substantial financial liabilities, which has become more of an issue for manufacturers as products, disease states and additional factors that previously […]
EVERSANA’s Chris Lagoerio, Vice President, Revenue Management participated in a panel session, “Innovative Approaches to 340B Claims Data Identification,” at the Medicaid & Government Pricing Congress alongside fellow industry leaders Andrew Brownlee, Associate Director, Berkeley Research Group; Kathleen Black, Chairperson and Director, Government Operations, Pfizer Inc; and Cathy Burton-Meza, Senior Manager, Audits & Compliance, Gilead. […]
Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’ gross-to-net. But how and where to invest valuable assets is a significant decision. The process of revenue management, including […]
Strategically pricing new therapies has always been vitally important for pharmaceutical manufacturers. After the 2022 passing of the historic legislative package, known as the Inflation Reduction Act (IRA), strategic pricing strategies have become especially pivotal. The IRA gives manufacturers less flexibility to adjust their pricing strategies due to penalties that are now applied for price […]
How Emerging Trends are Demanding a More Holistic View to Drive Maximum Value As the complexity of investments needed to secure patient access to therapy increases, so does the impact of these investments on a company’s net revenue. Each decision needs scrutiny, not only on its own merits and how it can affect patient access […]
The case for primary market research, Real-World Data (RWD), and deep healthcare experience combined to deliver targeted market access strategies. As diseases become more complex and market access becomes more restrictive, with multiple sources of market research and data analytic solutions available, pharmaceutical executives are often overwhelmed with various sources of information. Leaders must learn […]
NAVLIN Brief The European Commission has finally released its proposal to revise the European Union’s pharmaceutical legislation. The document includes proposals for a new Directive and a new Regulation, which revise and replace the existing pharmaceutical legislation via the largest reform in over 20 years The Commission proposes new incentives for AMR-related products, greater transparency […]
Biopharmaceutical companies have offered financial assistance for commercially covered patients’ out-of-pocket (OOP) cost sharing for 20+ years. However, in the ongoing evolution of controlling versus encouraging patient access to specific drugs, payers and biopharma also have a long history of one-upmanship. Are pharma motivations for offering copay assistance centered on the patient, their own bottom […]
